Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealthSpring Denosumab Coverage Update | OpenPayer
    Ask Trek AI about this page
    ModifiedHealthSpringPolicy RX501.140

    Denosumab and Associated Biosimilars for Non-Oncologic Indications

    Customize your policy alerts

    Sign up for healthspring Policy RX501.140 alerts

    Get alerted when Policy RX501.140 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical-necessity coverage of Prolia (denosumab) and FDA-approved denosumab biosimilars for adults with postmenopausal osteoporosis, osteoporosis in men, or glucocorticoid-induced osteoporosis. Oncologic indications are addressed under a separate HealthSpring policy.

    Policy Summary
    PayerHealthSpring
    PolicyDenosumab and Associated Biosimilars for Non-Oncologic Indications
    Policy CodePolicy RX501.140
    Change TypeModified
    Effective DateOct 20, 2026
    Next Review DateN/A
    Key ActionDocument the diagnosis, fragility-fracture history and/or pretreatment T-score, fracture-risk status when required, and current or planned glucocorticoid therapy when requesting coverage.
    SourceLink
    POLICY UPDATE CHANGES

    FDA-approved language was added to the medically necessary coverage statement and Note 2.

    Denosumab-adet (Ponlimsi) was added to the biosimilars identified in Note 2.

    Coverage criteria for glucocorticoid-induced osteoporosis were revised.

    Additional denosumab biosimilars were added to the identified products.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    18+Minimum age for covered use
    3Covered indication groups
    10FDA-approved biosimilars listed
    ≤ -2.5Bone-density threshold
    Non-FDA-approvedExcluded uses

    Covered and Non-Covered Uses

    Medically necessary indications

    Denosumab and its biosimilars may be considered medically necessary for any one of the following covered non-oncologic indications, when the applicable clinical criteria are met.

    Covered indication

    • Postmenopausal osteoporosis with a history of fragility fracture(s), or a pre-treatment T-score less than or equal to -2.5 and high risk for fracture.T-score ≤ -2.5 when using the bone-density pathway
    • Osteoporosis in men with a history of fragility fracture(s), or a pre-treatment T-score less than or equal to -2.5 and high risk for a fracture.T-score ≤ -2.5 when using the bone-density pathway
    • Glucocorticoid-induced osteoporosis

      • Osteoporosis evidence: A pre-treatment T-score less than or equal to -2.5 or a history of a fragility fracture.T-score ≤ -2.5 or history of fragility fracture
      • Glucocorticoid therapy: Currently receiving or initiating glucocorticoid therapy at an equivalent prednisone dose of at least 5 mg/day, with plans to continue for at least 6 months or more.Prednisone equivalent ≥5 mg/day for ≥6 months

    Denosumab (Prolia) and its FDA-approved biosimilars are considered experimental, investigational, and/or unproven when requested for any non-FDA-approved indication.

    Oncologic indications for denosumab and associated biosimilars are outside the scope of this policy. Direct requests for oncologic use to RX502.061.

    This policy does not address oncologic uses of denosumab.

    Coverage under this policy is limited to non-oncologic, FDA-labeled uses; oncologic uses of denosumab are not addressed.

    All non-FDA-approved indications for denosumab and its biosimilars are excluded as experimental, investigational, and/or unproven.

    Denosumab and its biosimilars are not medically necessary when requested for a non-FDA-approved indication.

    Codes and Clinical Thresholds

    HCPCS CodesHCPCS
    C9399
    J0897
    J3490
    J3590
    J9999
    Q5136
    Q5157
    Q5158
    Q5159
    Q5161
    1–10 of 15
    1/2
    CPT CodesCPT
    No codes listed
    HCPCS CodesHCPCS
    C9399
    J0897
    J3490
    J3590
    J9999
    Q5136
    Q5157
    Q5158
    Q5159
    Q5161
    1–10 of 15
    1/2
    Pretreatment T-score
    Pretreatment T-scoreLess than or equal to -2.5
    Applies toPostmenopausal osteoporosis, osteoporosis in men, and glucocorticoid-induced osteoporosis
    Additional requirementHigh fracture risk is required when using the bone-density pathway for postmenopausal osteoporosis or osteoporosis in men
    Minimum age
    Minimum age18 years or older
    Covered populationAdults receiving denosumab or an FDA-approved biosimilar

    Documentation, Safety, and Coverage Decisions

    Documentation Required

    Clinical Eligibility Documentation

    Document the covered diagnosis and supporting clinical information for adults 18 years of age or older. For osteoporosis indications, include a history of fragility fracture(s) or a pre-treatment T-score of ≤ -2.5 with high fracture risk, as applicable; for glucocorticoid-induced osteoporosis, also document current or planned glucocorticoid therapy.

    • Postmenopausal osteoporosis or osteoporosis in men: fragility fracture history OR pre-treatment T-score ≤ -2.5 and high fracture risk.
    • Glucocorticoid-induced osteoporosis: pre-treatment T-score ≤ -2.5 or fragility fracture, plus current or planned glucocorticoid therapy.
    Prior Authorization

    Evaluate Advanced Kidney Disease Safety

    Before initiating denosumab in a patient with advanced chronic kidney disease, including a patient receiving dialysis, evaluate for CKD-MBD because the condition substantially increases the risk of severe hypocalcemia. Treatment should be supervised by a healthcare provider experienced in diagnosing and managing CKD-MBD.

    Therapy Background

    Denosumab and its FDA-approved biosimilars are antiresorptive therapies used for selected adult osteoporosis indications, including postmenopausal osteoporosis, osteoporosis in men, and glucocorticoid-induced osteoporosis. Coverage is limited to qualifying non-oncologic uses supported by the applicable fracture history, bone-density, fracture-risk, and glucocorticoid-therapy criteria.

    Clinical Definitions

    CKD-MBD
    TermChronic kidney disease mineral and bone disorder (CKD-MBD)
    Clinical relevanceCKD-MBD greatly increases the risk of hypocalcemia after denosumab administration
    Required evaluationPatients with advanced chronic kidney disease should be evaluated for CKD-MBD before starting denosumab
    Fragility fracture
    Fragility fractureA fracture resulting from a fall from standing height or another low-trauma event
    Qualifying historyA history of fragility fracture(s) may satisfy an osteoporosis coverage criterion
    Examples cited

    Initial Treatment Eligibility

    Adult eligibility

    Initial treatment may be considered when the following adult eligibility requirement is met and an applicable indication-specific criterion is satisfied.

    Adult eligibility: The individual is 18 years of age or older.≥18 years

    Postmenopausal or male osteoporosis

    For postmenopausal osteoporosis or osteoporosis in men, meet any one of the following criteria.

    Osteoporosis qualification

    • Fragility fracture pathway: A history of fragility fracture(s).

    Administration Setting

    Billing Rule

    Administer in the office

    Denosumab should be administered by a healthcare provider in the office setting.

    Covered Denosumab Products

    Billing Rule

    Jubbonti coverage

    Denosumab-bbdz (Jubbonti) is included as a denosumab biosimilar covered under the policy when used for a covered non-oncologic indication.

    Billing Rule

    Ospomyv coverage

    Denosumab-dssb (Ospomyv) is included as a denosumab biosimilar covered under the policy when used for a covered non-oncologic indication.

    Billing Rule

    Stoboclo coverage

    Denosumab-bmwo (Stoboclo) is included as a denosumab biosimilar covered under the policy when used for a covered non-oncologic indication.

    Billing Rule

    Conexxence coverage

    Policy Summary
    PayerHealthSpring
    PolicyDenosumab and Associated Biosimilars for Non-Oncologic Indications
    Policy CodePolicy RX501.140
    Change TypeModified
    Effective DateOct 20, 2026
    Next Review DateN/A
    Key ActionDocument the diagnosis, fragility-fracture history and/or pretreatment T-score, fracture-risk status when required, and current or planned glucocorticoid therapy when requesting coverage.
    SourceLink
    On This Page
    Covered and Non-Covered UsesCodes and Clinical ThresholdsDocumentation, Safety, and Coverage DecisionsTherapy BackgroundClinical DefinitionsInitial Treatment EligibilityAdministration SettingCovered Denosumab Products
    Age-related coverage limitationUse in individuals younger than 18 years is not covered under this policy's non-oncologic criteria
    DXA T-score for osteoporosis
    DXA T-score for osteoporosisLess than or equal to -2.5 standard deviations
    Measurement methodBone mineral density measured by dual-energy x-ray absorptiometry (DXA)
    Reference populationYoung adult female reference mean
    FRAX major osteoporotic fracture probability
    Major osteoporotic fracture probabilityFRAX 10-year probability of at least 20 percent
    Assessment toolFracture Risk Assessment Tool (FRAX)
    Clinical useSupports a clinical diagnosis when fracture risk is clearly elevated
    FRAX hip fracture probability
    Hip fracture probabilityFRAX 10-year probability of at least 3 percent
    Assessment period10 years
    Clinical useSupports a clinical diagnosis when fracture risk is clearly elevated
    FRAX major osteoporotic fracture risk
    Major osteoporotic fracture risk10-year risk of at least 20 percent
    U.S. thresholdThe United States threshold for major osteoporotic fracture risk is at least 20 percent
    FRAX populationUsed to assess fracture risk in patients with low BMD or other risk factors
    FRAX hip fracture risk
    Hip fracture risk10-year risk of at least 3 percent
    U.S. thresholdThe United States threshold for hip fracture risk is at least 3 percent
    Assessment toolFracture Risk Assessment Tool (FRAX)
    Osteoporotic BMD T-score
    Osteoporotic BMD T-scoreLess than -2.5
    Low BMD comparison rangeT-scores from -1.0 to -2.5 are cited as low bone mass or osteopenia
    Clinical contextFracture risk may also be elevated when a T-score is between -1.0 and -2.5
    Low BMD range
    Low BMD range-1.0 to -2.5
    ClassificationLow bone mass or osteopenia
    Additional risk factorTreatment consideration may depend on additional fracture-risk factors, including FRAX risk
    Long-term glucocorticoid exposure
    Long-term glucocorticoid exposureAt least 3 months
    Therapy scopePatients scheduled to start or already taking long-term glucocorticoid therapy
    Dose contextThe cited recommendation applies to glucocorticoid therapy in any dose and for any reason
    Prednisone-equivalent dose
    Prednisone-equivalent doseAt least 7.5 mg/day
    Therapy typeLong-term glucocorticoid therapy
    Duration citedLonger than 3 months
    Pre-treatment T-score
    Pre-treatment T-scoreLess than or equal to -2.5
    Applicable indicationGlucocorticoid-induced osteoporosis may qualify with this T-score or a history of fragility fracture
    Therapy requirementCurrent or planned glucocorticoid therapy must also meet the policy's dose and duration criteria
    Glucocorticoid therapy
    Prednisone-equivalent doseAt least 5 mg/day
    Planned durationAt least 6 months
    Coverage contextThe individual must be currently receiving or initiating glucocorticoid therapy for glucocorticoid-induced osteoporosis
    • Evaluate with intact parathyroid hormone, serum calcium, 25(OH) vitamin D, and 1,25(OH)2 vitamin D.
    • Assess and document the presence or absence of CKD-MBD before treatment.
    Documentation Required

    Administration and Pregnancy Precautions

    Rule out pregnancy before denosumab administration. Denosumab must be administered by a healthcare provider.

    • Confirm pregnancy has been ruled out before each applicable administration.
    • Document administration by a healthcare provider.

    Unsupported block type: billing_rule

    Denial Risk

    Non-FDA-Approved Indication

    Denosumab and its biosimilars are considered experimental, investigational, and/or unproven for all non-FDA-approved indications. Coverage may be denied when the requested use does not correspond to an FDA-approved indication.

    • Confirm that the requested indication is FDA-approved and supported by the policy’s coverage criteria.
    Denial Risk

    Age or Clinical Criteria Not Met

    Coverage may be denied when the individual is younger than 18 years or does not meet the applicable osteoporosis criteria. Denosumab is not indicated for pediatric patients younger than 18 years.

    • Verify the patient is at least 18 years old.
    • Document the applicable fragility fracture, T-score, fracture-risk, and glucocorticoid criteria.
    Denial Risk

    Prior Bisphosphonate-Associated Jaw Necrosis

    Patients with a history of jaw necrosis due to bisphosphonate therapy should not use denosumab. Identify and document this history before treatment; it may make therapy inappropriate and support a coverage denial.

    • Screen for prior bisphosphonate-associated jaw necrosis.
    • Do not proceed with denosumab when this history is present.

    Unsupported block type: billing_rule

    Denial Risk

    Non-FDA-Approved Uses

    All uses of denosumab and its biosimilars that are not FDA-approved are considered experimental, investigational, and/or unproven under this policy.

    • Confirm the requested use is an FDA-approved non-oncologic indication before requesting coverage.
    • Oncologic indications are addressed under RX502.061 Oncology and Supportive Care Medications.
    Fragility fractures may occur spontaneously or from minor trauma, particularly in the spine, hip, wrist, humerus, rib, or pelvis
    Normal bone mass
    Normal bone massBMD within 1.0 standard deviation of the young adult female reference mean
    T-score rangeT-score greater than or equal to -1.0 standard deviation
    Measurement basisClassification is based on BMD measured by DXA
    Low bone mass or osteopenia
    Low bone mass or osteopeniaBMD more than 1.0 but less than 2.5 standard deviations below the young adult female reference mean
    T-score rangeT-score less than -1.0 and greater than -2.5 standard deviations
    Measurement basisClassification is based on BMD measured by DXA
    Osteoporosis
    OsteoporosisBMD 2.5 or more standard deviations below the young adult female reference mean
    T-score thresholdT-score less than or equal to -2.5 standard deviations
    Measurement basisClassification is based on BMD measured by DXA
    Severe or established osteoporosis
    Severe or established osteoporosisBMD more than 2.5 standard deviations below the young adult female reference mean with one or more fragility fractures
    Bone-density findingT-score is less than -2.5 standard deviations
    Fracture requirementOne or more fragility fractures must be present
    Fracture Risk Assessment Tool (FRAX)
    FRAXA computer-based calculator estimating fracture probability
    Estimated outcomes10-year probability of hip fracture and major osteoporotic fracture
    Population and inputsUntreated patients aged 40 to 90 years, using clinical risk factors with or without femoral neck BMD
    Bone density and fracture risk pathway:
    A pre-treatment T-score less than or equal to -2.5 and high risk for fracture.
    T-score ≤ -2.5; high fracture risk

    Both the T-score and high-fracture-risk elements are required.

    Glucocorticoid-induced osteoporosis

    For glucocorticoid-induced osteoporosis, meet all of the following criteria.

    • Bone density or fracture criterion

      • A pre-treatment T-score less than or equal to -2.5.T-score ≤ -2.5
      • A history of a fragility fracture.
    • Glucocorticoid therapy criterion: The individual is currently receiving or will be initiating glucocorticoid therapy at an equivalent prednisone dose of at least 5 mg/day, with plans to continue prednisone for at least 6 months or more.Prednisone equivalent ≥5 mg/day for ≥6 months

      Both the dose and planned duration are required.

    Initial therapy eligibility

    Initial coverage requires an FDA-approved non-oncologic indication and satisfaction of the applicable clinical criteria.

    • FDA-approved indication: The requested use is an FDA-approved non-oncologic indication.

      Non-FDA-approved indications are considered experimental, investigational, and/or unproven.

    • Applicable clinical criteria

      • Postmenopausal osteoporosis with a history of fragility fracture(s), or a pre-treatment T-score less than or equal to -2.5 and high risk for fracture.
      • Osteoporosis in men with a history of fragility fracture(s), or a pre-treatment T-score less than or equal to -2.5 and high risk for a fracture.
      • Glucocorticoid-induced osteoporosis with a pre-treatment T-score less than or equal to -2.5 or a history of a fragility fracture, plus glucocorticoid therapy at an equivalent prednisone dose of at least 5 mg/day with plans to continue for at least 6 months or more.T-score ≤ -2.5 or fragility fracture; prednisone equivalent ≥5 mg/day for ≥6 months

    Denosumab-bnht (Conexxence) is included as a denosumab biosimilar covered under the policy when used for a covered non-oncologic indication.

    Billing Rule

    Osvyrti coverage

    Denosumab-desu (Osvyrti) is included as a denosumab biosimilar covered under the policy when used for a covered non-oncologic indication.

    Billing Rule

    Bosaya coverage

    Denosumab-kyqq (Bosaya) is included as a denosumab biosimilar covered under the policy when used for a covered non-oncologic indication.

    Billing Rule

    Enoby coverage

    Denosumab-qbde (Enoby) is included as a denosumab biosimilar covered under the policy when used for a covered non-oncologic indication.

    Billing Rule

    Bildyos coverage

    Denosumab-nxxp (Bildyos) is included as a denosumab biosimilar covered under the policy when used for a covered non-oncologic indication.

    Billing Rule

    Boncresa coverage

    Denosumab-mobz (Boncresa) is included as a denosumab biosimilar covered under the policy when used for a covered non-oncologic indication.

    Billing Rule

    Ponlimsi coverage and label reference

    Denosumab-adet (Ponlimsi) is included as a denosumab biosimilar covered under the policy when used for a covered non-oncologic indication. The policy’s FDA label references include the Ponlimsi prescribing label.

    Billing Rule

    Prolia coverage

    Denosumab (Prolia) is the reference denosumab product covered under the policy when used for a covered non-oncologic indication.